The Chicago Tribune reports that investment firm Blackstone Group is the leader in the sweepstakes to buy Allscripts, but the companies are far apart on price and there’s no certainty of a deal being made.
On that news, Allscripts’ stock price dropped 11 percent on Nov. 30, though it fell by only 2 cents more in late morning trading on Dec. 3. Allscripts on Nov. 8 reported weak financial performance for the third quarter of 2012, saying providers were deferring purchase decisions and waiting for new product releases. CEO Glen Tullman confirmed the company was evaluating “strategic alternatives,” which Bloomberg News first reported in October. Tullman blamed the “noise” of acquisition talk on lower bookings in the third quarter and said, “We think we’ll be well-positioned once we get past the noise.”
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access